Literature DB >> 18523889

The use of beta-cyclodextrin in the manufacturing of disintegrating pellets with improved dissolution performances.

Lucia Zema1, Luca Palugan, Alessandra Maroni, Anastasia Foppoli, Maria Edvige Sangalli, Andrea Gazzaniga.   

Abstract

It has recently been highlighted that the release behavior of pellets containing microcystalline cellulose (MCC) as the spheronizing agent may be impaired by the lack of disintegration. Although alternative spheronizing excipients have been proposed, their overall advantages have not thoroughly been assessed. In the present work, the possible use of beta-cyclodextrin (betaCD) was therefore explored for the manufacturing of pellets with a potential for effective disintegration and immediate release of poorly soluble active ingredients. MCC/betaCD powder formulations containing no drug or model drugs with different water solubility, able to form inclusion compounds with the employed cyclodextrin, were pelletized by agglomeration in rotary fluid bed equipment. By applying successive statistical experimental designs, the most critical formulation and operating parameters were identified and optimal manufacturing processes were ultimately set up. High yields of pellets provided with satisfactory physical-technological characteristics were obtained using powder formulations with up to 80% betaCD. Based on dissolution testing results, the suitability of betaCD for the preparation of disintegrating MCC-containing pellets with improved dissolution performance was finally demonstrated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523889      PMCID: PMC2976967          DOI: 10.1208/s12249-008-9106-0

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  21 in total

1.  Development of fast-disintegrating pellets in a rotary processor.

Authors:  Jakob Kristensen; Torben Schaefer; Peter Kleinebudde
Journal:  Drug Dev Ind Pharm       Date:  2002-11       Impact factor: 3.225

2.  Wet spheronization by rotary processing--a multistage single-pot process for producing spheroids.

Authors:  L Gu; C V Liew; P W S Heng
Journal:  Drug Dev Ind Pharm       Date:  2004-02       Impact factor: 3.225

3.  Immediate release of poorly soluble drugs from starch-based pellets prepared via extrusion/spheronisation.

Authors:  Aleksandra Dukić-Ott; Jean Paul Remon; Paul Foreman; Chris Vervaet
Journal:  Eur J Pharm Biopharm       Date:  2007-04-29       Impact factor: 5.571

4.  The use of beta-cyclodextrin as a pelletization agent in the extrusion/spheronization process.

Authors:  A Gazzaniga; M E Sangalli; G Bruni; L Zema; C Vecchio; F Giordano
Journal:  Drug Dev Ind Pharm       Date:  1998-09       Impact factor: 3.225

5.  Effect of common classes of excipients on extrusion-spheronization.

Authors:  M F Law; P B Deasy
Journal:  J Microencapsul       Date:  1997 Sep-Oct       Impact factor: 3.142

6.  Direct pelletization in a rotary processor controlled by torque measurements. II: effects of changes in the content of microcrystalline cellulose.

Authors:  J Kristensen; T Schaefer; P Kleinebudde
Journal:  AAPS PharmSci       Date:  2000

7.  Starch-dextrin mixtures as base excipients for extrusion-spheronization pellets.

Authors:  S Almeida Prieto; J Blanco Méndez; F J Otero Espinar
Journal:  Eur J Pharm Biopharm       Date:  2005-04       Impact factor: 5.571

8.  Preliminary assessment of carrageenan as excipient for extrusion/spheronisation.

Authors:  Martin Bornhöft; Markus Thommes; Peter Kleinebudde
Journal:  Eur J Pharm Biopharm       Date:  2005-01       Impact factor: 5.571

9.  Functionality of cross-linked polyvinylpyrrolidone as a spheronization aid: a promising alternative to microcrystalline cellulose.

Authors:  Celine V Liew; Li Gu; Josephine L P Soh; Paul W S Heng
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

10.  Disintegrating pellets from a water-insoluble pectin derivative produced by extrusion/spheronisation.

Authors:  Ingunn Tho; Sverre Arne Sande; Peter Kleinebudde
Journal:  Eur J Pharm Biopharm       Date:  2003-11       Impact factor: 5.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.